Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of July 2020, with a filing date of July 14, 2020. The document serves as a transaction notification regarding share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them (PCAs). The transactions were executed on July 10, 2020, on the London Stock Exchange (XLON) and the New York Stock Exchange (XNYS).
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics for the company. It exclusively details specific share transactions.
| Instrument | Transaction Type | Price | Total Volume (Shares/ADS) |
|---|---|---|---|
| Ordinary Shares (GBP) | Acquisition via Dividend Re-investment | £15.7733 | 11,480.005 |
| American Depositary Shares (USD) | Acquisition via Dividend Re-investment | $40.0723 | 1,036.081 |
Note: Total volumes are aggregated from individual PDMR transactions listed in the filing.
Material Changes
The filing does not report material changes to the company's business operations, financial condition, or strategic direction. The only changes reported are the incremental increases in share ownership by specific executives resulting from the automatic re-investment of dividends paid on July 9, 2020.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a statutory disclosure of insider trading activity compliant with regulatory requirements.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of Ordinary Shares or ADSs resulting from the re-investment of dividends, not open-market purchases or sales.
- Participants: Transactions involved 14 individuals, including the CEO (Ms. E. Walmsley), President of Global Vaccines (Mr. R. Connor), and other senior executives and their associated persons.
- Timing: All transactions occurred on July 10, 2020, immediately following the dividend payment date of July 9, 2020.
- Valuation: The share price at the time of transaction was £15.7733 for Ordinary Shares and $40.0723 for ADSs.